Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
Revenue (TTM)
$16 Mln
Net Profit (TTM)
$-31 Mln
ROE
-1.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
54.26
EV/EBITDA
-0.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
34,963,000
CFO
$-281.64 Mln
EBITDA
$-344.59 Mln
Net Profit
$-346.41 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
DermTech (DMTK)
| -97.9 | -44.7 | -89.6 | -98.4 | -90.0 | -64.2 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
DermTech (DMTK)
| -1.1 | -88.8 | -51.3 | 161.6 | -39.3 | 4.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
DermTech (DMTK)
|
0.0 | 3.3 | 15.7 | -89.6 | -580.4 | -158.6 | -- | 0.0 |
| 0.4 | 94.9 | 9.9 | -83.8 | -721.2 | -- | -- | 7.1 | |
| 459.9 | 809.4 | 181.6 | 12.6 | 6.0 | 5.2 | 64.5 | 3.4 |
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT),... an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California. On June 18, 2024, DermTech, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
CFO, Treasurer & Secretary
Mr. Kevin Sun M.B.A.
CFO, Treasurer & Secretary
Mr. Kevin Sun M.B.A.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of DermTech Inc (DMTK) is $0.04 (NASDAQ) as of 29-Aug-2024 09:30 EDT. DermTech Inc (DMTK) has given a return of -90.03% in the last 3 years.
Since, TTM earnings of DermTech Inc (DMTK) is negative, P/E ratio is not available.
The P/B ratio of DermTech Inc (DMTK) is 0.02 times as on 29-Aug-2024, a 99 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of DermTech Inc (DMTK) are Rs -- and Rs -- as of 03-Apr-2026.
DermTech Inc (DMTK) has a market capitalisation of $ 3 Mln as on 29-Aug-2024. As per SEBI classification, it is a Small Cap company.
Before investing in DermTech Inc (DMTK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.